Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 5/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.36 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD1 | P21728 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | DRD5 | P21918 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6433933 | 0.92 | L3MBTL1 (0.36) | GSK3BRORCSIRT2SIRT1ALDH1A1 | |
| SCHEMBL6433641 | 0.88 | KMT2A (0.36) | KMT2AMEN1GSK3BRORCSIRT2 | |
| SCHEMBL6433734 | 0.85 | GSK3B (0.38) | KMT2AMEN1GSK3BRORCSIRT2 | |
| SCHEMBL7142827 | 0.83 | KMT2A (0.43) | KMT2AMEN1GSK3BRORCALDH1A1 | |
| SCHEMBL7139979 | 0.81 | ALDH1A1 (0.40) | KMT2AMEN1GSK3BSIRT2SIRT1 | |
| SCHEMBL7141522 | 0.80 | ALDH1A1 (0.42) | KMT2AMEN1GSK3BSIRT2SIRT1 | |
| SCHEMBL5868814 | 0.79 | PTGES (0.41) | KMT2AMEN1GSK3BSIRT2SIRT1 | |
| SCHEMBL5869052 | 0.79 | GSK3B (0.41) | GSK3BRORCSIRT2SIRT1ALDH1A1 | |
| SCHEMBL14753361 | 0.79 | GSK3B (0.44) | GSK3BRORCSIRT2SIRT1 | |
| SCHEMBL5868942 | 0.79 | ERCC5 (0.44) | KMT2AMEN1GSK3BALDH1A1LTB4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1379522-B1 | DIHYDRO-BENZO(b)(1,4)DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS I | HOFFMANN LA ROCHE (CH) | 2005-01-26 | — | — | EP | disclosed |
| US-6548495-B2 | Metabotropic glutamate receptor agonist for treatment or prevention of acute and/or chronic neurological disorders | HOFFMANN-LA ROCHE INC. | 2003-04-15 | — | — | US | disclosed |
| US-20020198197-A1 | Dihydro-benzo [b] [1,4] diazepin-2-one derivatives | HOFFMANN-LA ROCHE INC. | 2002-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198197-A1 | Dihydro-benzo [b] [1,4] diazepin-2-one derivatives | BDKRB1, BDKRB2, GRIN1 | KMT2A 1451/4885MEN1 1315/4885GSK3B 1356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.